Caricamento quotazioni...
Previsioni
| Acquista |
13 |
| Mantieni |
2 |
| Vendi |
1 |
Discussioni nella community
Non ci sono ancora discussioni su questo asset.
Avvia discussioneNotizie Vai al feed delle notizie
Cellectis reports quarterly loss per share of $0.26 and declining revenue
Cellectis reported earnings per share of -$0.26 for the most recent quarter, after -$0.080 in the year-ago quarter. Quarterly revenue fell to $10.4 million (-17.74% versus $12.6 million). For the full year, the company shows a loss per share of -$0.670, while annual revenue rose sharply to $73.17 million (±76.61% versus $41.43 million). » Altro su finanzen.net
Cellectis beats Q4 2025 revenue and EPS forecasts, stock rises
Cellectis reported Q4 2025 EPS of -$0.19 (forecast -$0.2948) and revenue of $17.1 million (forecast $10.02 million), both well above expectations. The stock rose 2.01% in premarket trading to $3.55. Cash resources of $211 million secure the company’s financial runway into the second half of 2027. The company highlights progress on the Lasme‑Cel and Eti‑Cel programmes and the validation of internal manufacturing capacities. » Altro su de.investing.com
Cellectis: arbitration panel partially terminates license agreement with Servier
An arbitration panel has partially terminated the 2019 license, development and commercialization agreement between Cellectis and Servier. The decision specifically concerns the product UCART19 V1 (also ALLO-501) and obliges Cellectis, upon request, to enter into good-faith negotiations with Allogene regarding a direct licensing arrangement. All other claims brought in the arbitration were dismissed. » Altro su de.investing.com
Cellectis achieves breakthrough in non-viral gene insertion method
Cellectis and Moligo present in Nature Communications a non-viral gene insertion method for hematopoietic stem and progenitor cells (HSPCs) based on enzymatically produced circular single-stranded DNA (CssDNA). The circular ssDNA format reached insertion rates above 40% and was 3- to 5-fold more efficient than linear ssDNA; in mouse models, CssDNA-edited HSPCs showed better expansion and retention of edits than with AAV6. The collaboration aims to provide a scalable alternative to viral vectors and strengthen Cellectis' position in gene editing, while analysts see a price target of $7.50 and the company, despite strong revenue growth, is not yet profitable. » Altro su de.investing.com
Cellectis reports strong phase‑1 data for leukemia therapy lasme‑cel
Cellectis released promising phase‑1 data from the BALLI‑01 study of lasme‑cel (UCART22) in relapsed/refractory B‑ALL: overall response rate 68% (manufacturing process 2), 83% at the dose recommended for phase‑2 and 100% in the phase‑2 target population. In that target group, 56% achieved complete remission (CR/CRi) and about 80% were minimal residual disease (MRD) negative; 78% of patients eligible for transplant received one. The therapy showed activity even in heavily pretreated patients and was generally well tolerated. Cellectis has initiated a registration‑enabling phase‑2 study (first patient expected Q4 2025) and is targeting a BLA submission in 2028; Q2 financials showed mixed signals with revenue above forecast but an EPS miss. » Altro su de.investing.com
Dati finanziari dell'azienda
| (EUR) | settembre 2026 | YoY |
|---|---|---|
| Ricavi | 3,76 Mln | 89,30% |
| Utile lordo | 1,27 Mln | 96,13% |
| Utile netto | -61,47 Mln | 10.537,01% |
| EBITDA | -27,79 Mln | 460,63% |
Dati fondamentali
| Metrica | Valore |
|---|---|
Capitalizzazione di mercato | 71,53 Mln € |
Numero di azioni | 72,33 Mln |
Massimo/minimo a 52 settimane | 4,75 € - 0,90 € |
| Dividendi | No |
Beta | 2,91 |
Rapporto P/E | -0,85 |
Rapporto PEG | 0,01 |
Rapporto P/B | -6,20 |
Rapporto P/S | 3,12 |
Profilo aziendale
Cellectis S.A., una società biotecnologica in fase clinica, sviluppa prodotti di immuno-oncologia basati su linfociti T geneticamente modificati che esprimono recettori antigenici chimerici per colpire e distruggere le cellule tumorali. L'azienda opera attraverso due segmenti, Therapeutics e Plants. La società sta sviluppando UCART19, un candidato prodotto a base di linfociti T allogenici per il trattamento di neoplasie ematologiche che esprimono CD19, come la leucemia linfoblastica acuta; ALLO-501 e ALLO-501A per il trattamento del linfoma diffuso a grandi cellule B recidivante/refrattario e del linfoma follicolare; ALLO-316 per il trattamento del carcinoma a cellule renali; UCART123 per il trattamento della leucemia mieloide acuta; e UCART22 per il trattamento della leucemia linfoblastica acuta a cellule B. Sta inoltre sviluppando UCARTCS1 e ALLO-715 per il trattamento del mieloma multiplo. La società ha alleanze strategiche con Allogene Therapeutics, Inc.; Les Laboratoires Servier; The University of Texas M.D. Anderson Cancer Center; e Iovance Biotherapeutics, nonché una collaborazione strategica di ricerca e sviluppo con Cytovia Therapeutics, Inc. Cellectis S.A. è stata fondata nel 1999 ed ha sede a Parigi, in Francia.
| Nome | Cellectis |
| CEO | Andre Choulika |
| Sede centrale | Paris,
if Francia |
| Sito web | |
| Quotazione in borsa | 07/02/2007 |
| Dipendenti | 227 |
Deep Dive
Simboli di borsa
| Borsa | Simbolo |
|---|---|
Euronext | ALCLS.PA |
Pnk | CMVLF |
Frankfurt | ZVA.F |
Düsseldorf | ZVA.DU |
London | 0WA2.L |
Paris | ALCLS.PA |
München | ZVA.MU |